Tafasitamab
Monjuvi · Anti-CD19 antibody
Tumor lysis and infusion reactions in lymphoma.
Poteligeo · MOG
Anti-CCR4 antibody · approved 2018 · 6 citations · FAERS AKI reporting ROR 2.10 (95% CI 1.51–2.90, 37 AKI reports)
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
Defucosylated anti-CCR4 antibody for cutaneous T-cell lymphoma — renal-relevant risks are treatment-related tumor lysis and rare AKI, not a direct nephropathy.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Drug rash and infusion reactions are characteristic; tumor lysis occurred in roughly 2-3% in some series. AKI is rare and largely secondary to tumor lysis or volume shifts; a discrete AKI incidence is not well quantified. Reported rate: tumor lysis syndrome in 2.5% — 484 patients (safety analysis population) with CCR4-positive relapsed or refractory adult T-cell leukemia-lymphoma in a… (Ishitsuka 2017, PMID 28597329).Source: Kim et al., Lancet Oncol 2018 (MAVORIC); Ishitsuka et al., Int J Hematol 2017
Tumor lysis early in responders.
Distilled from: “Infusion reactions early; rash over weeks; tumor lysis early in responders.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Tap a signature to trace where it strikes the nephron.
Representative incidence
Functional / pre-renal — reduced perfusion upstream of the nephron; no single structural segment is injured.
Prerenal / Hemodynamic AKI: functional / pre-renal, no single structural segment injured.
Prerenal / Hemodynamic AKI
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Defucosylated humanized monoclonal antibody against CC chemokine receptor 4 (CCR4), expressed on malignant T cells and regulatory T cells. Glycoengineering markedly enhances antibody-dependent cellular cytotoxicity, depleting CCR4-positive cells in mycosis fungoides and Sezary syndrome.
6 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Everything below is FAERS — adverse events someone chose to report, about 1,908 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
346 of 1,908 reports
Reported with hospitalization
452 of 1,908 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 6 of the 1,908 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Mogamulizumab sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Monjuvi · Anti-CD19 antibody
Tumor lysis and infusion reactions in lymphoma.
Rydapt · FLT3 / multikinase inhibitor
Tumor lysis, edema and QT in AML/mastocytosis.
Tazverik · EZH2 inhibitor
Tumor lysis; generally low direct renal toxicity.
Ziihera · HER2 bispecific antibody
2024 biliary-tract HER2 bispecific; renal data emerging.
Bizengri · HER2×HER3 bispecific antibody
2024 NRG1-fusion bispecific; mostly grade 1-2 AEs — at most diarrhea-related prerenal risk, no CRS/TLS mechanism.
Darzalex · Anti-CD38 antibody
Tumor lysis; usable in renal impairment.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.